Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1

Chen,Jianguo; Chen,Yang; He,Qiyang

doi:10.3892/ijo.2012.1668

Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1

Authors:
- Jianguo Chen
- Yang Chen
- Qiyang He
View Affiliations

Affiliations: Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P.R. China
Published online on: October 16, 2012 https://doi.org/10.3892/ijo.2012.1668
Pages: 2245-2252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bleomycin is a first-line clinically used antitumor antibiotic for effective treatment of certain types of cancer in combination with other antitumor agents. Its action is affected by bleomycin hydrolase (BLH), DNA repair enzymes, membrane transport proteins and other cellular factors. To clarify whether BLH confers the resistance to bleomycin in tumor cells, it is necessary to further investigate the roles of BLH and its combination with other factors such as caveolin-1 in the action of bleomycin. In this study fourteen human cell lines were used for determination of bleomycin action and roles of BLH and caveolin-1. The relationship between action of bleomycin and cellular amount of BLH was detected by the MTT method and western blotting in the human leukemia cell line HL-60, HeLa cervical cancer cells and HaCaT immortalized keratinocyte cells. The sensitivity to bleomycin was increased in HeLa cells after knockdown of BLH mRNA by RNA interference. There is no relationship between caveolin-1 levels and action of bleomycin, although the distribution of the cell cycle was altered in the caveolin-1-knockdown HeLa cells after treatment with bleomycin. In addition, regulation of BLH and caveolin-1 expression in HeLa and HaCaT cells was observed in a concentration-dependent manner after exposure to bleomycin. In conclusion, bleomycin hydrolase is one of the biomarkers for determination of bleomycin action. Although caveolin-1 can respond to bleomycin treatment, it is unrelated to bleomycin sensitivity.

View Figures

View References

1.	Chen J and Stubbe J: Bleomycins: towards better therapeutics. Nat Rev Cancer. 5:102–112. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Lazo JS and Humphreys CJ: Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci USA. 80:3064–3068. 1983. View Article : Google Scholar : PubMed/NCBI
3.	Ibrahimi OA and Anderson RR: Images in clinical medicine. Bleomycin-induced flagellate hyperpigmentation. N Engl J Med. 363:e362010. View Article : Google Scholar : PubMed/NCBI
4.	Xu H, Yu L, Zhang X and Wang S: Isolation, purification and structure determination of boningmycin (Z-893). J Chin Antibiot. 28:465–467. 2003.
5.	Gao N, Shang B, Zhang X, et al: Potent antitumor actions of the new antibiotic boningmycin through induction of apoptosis and cellular senescence. Anticancer Drugs. 22:166–175. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Lazo JS, Boland CJ and Schwartz PE: Bleomycin hydrolase activity and cytotoxicity in human tumors. Cancer Res. 42:4026–4031. 1982.PubMed/NCBI
7.	Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J and Lazo JS: The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci USA. 96:4680–4685. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Pei Z, Calmels TP, Creutz CE and Sebti SM: Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells. Mol Pharmacol. 48:676–681. 1995.PubMed/NCBI
9.	Lazo JS, Merrill WW, Pham ET, Lynch TJ, McCallister JD and Ingbar DH: Bleomycin hydrolase activity in pulmonary cells. J Pharmacol Exp Ther. 231:583–588. 1984.PubMed/NCBI
10.	Sebti SM, Jani JP, Mistry JS, Gorelik E and Lazo JS: Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res. 51:227–232. 1991.PubMed/NCBI
11.	Wang H and Ramotar D: Cellular resistance to bleomycin in Saccharomyces cerevisiae is not affected by changes in bleomycin hydrolase levels. Biochem Cell Biol. 80:789–796. 2002.PubMed/NCBI
12.	Einhorn LH: Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 99:4592–4595. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Aouida M, Poulin R and Ramotar D: The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 285:6275–6284. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Linge A, Weinhold K, Bläsche R, Kasper M and Barth K: Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int J Biochem Cell Biol. 39:1964–1974. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Linge A, Meleady P, Henry M, Clynes M, Kasper M and Barth K: Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts. Int J Biochem Cell Biol. 43:98–105. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Wang XM, Zhang Y, Kim HP, et al: Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 203:2895–2906. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Ferrando AA, Velasco G, Campo E and Lopez-Otin C: Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res. 56:1746–1750. 1996.PubMed/NCBI
18.	de Haas EC, Zwart N, Meijer C, et al: Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol. 26:1817–1823. 2008.PubMed/NCBI
19.	Brömme D, Rossi AB, Smeekens SP, Anderson DC and Payan DG: Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry. 35:6706–6714. 1996.PubMed/NCBI
20.	Sikic B: Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 5:81–91. 1986.PubMed/NCBI
21.	Sleijfer S: Bleomycin-induced pneumonitis. Chest. 120:617–624. 2001. View Article : Google Scholar
22.	Simpson AB, Paul J, Graham J and Kaye SB: Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95: a review of patients with germ cell tumours. Br J Cancer. 78:1061–1066. 1998.PubMed/NCBI
23.	Nagase T, Uozumi N, Ishii S, et al: A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med. 8:480–484. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Oga T, Matsuoka T, Yao C, et al: Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med. 15:1426–1430. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Avivi-Green C, Singal M and Vogel WF: Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 174:420–427. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Barranco SC, Haenelt BR and Gee EL: Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res. 38:656–660. 1978.PubMed/NCBI
28.	Okamura Y, Nomoto S, Hayashi M, et al: Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Lett. 312:150–157. 2011. View Article : Google Scholar : PubMed/NCBI
29.	Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B, Newman RA and Kennedy KA: Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 49:185–190. 1989.PubMed/NCBI
30.	Yen HC, Li SH, Majima HJ, et al: Up-regulation of antioxidant enzymes and coenzyme Q(10) in a human oral cancer cell line with acquired bleomycin resistance. Free Radic Res. 45:707–716. 2011. View Article : Google Scholar : PubMed/NCBI
31.	Belanger MM, Roussel E and Couet J: Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs. 14:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Tirado O, MacCarthy C, Fatima N, Villar J, Mateo-Lozano S and Notario V: Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing’s sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 126:426–436. 2010.PubMed/NCBI
33.	Parton RG and Simons K: The multiple faces of caveolae. Nat Rev Mol Cell Biol. 8:185–194. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Park WY, Park JS, Cho KA, Kim DI, Ko YG, Seo JS and Park SC: Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem. 275:20847–20852. 2000. View Article : Google Scholar : PubMed/NCBI
35.	Volonte D, Zhang K, Lisanti MP and Galbiati F: Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell. 13:2502–2517. 2002. View Article : Google Scholar : PubMed/NCBI
36.	Dasari A, Bartholomew JN, Volonte D and Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen -activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 66:10805–10814. 2006. View Article : Google Scholar
37.	Cho KA, Ryu SJ, Park JS, Jang IS, Ahn JS, Kim KT and Park SC: Senescent phenotype can be reversed by reduction of caveolin status. J Biol Chem. 278:27789–27795. 2003. View Article : Google Scholar : PubMed/NCBI
38.	Robles SJ and Adami GR: Agents that cause DNA double strand breaks lead to p16^INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 16:1113–1123. 1998. View Article : Google Scholar : PubMed/NCBI
39.	Aoshiba K, Tsuji T and Nagai A: Bleomycin induces cellular senescence in alveolar epithelial cells. Eur Respir J. 22:436–443. 2003. View Article : Google Scholar : PubMed/NCBI
40.	Baus F, Gire V, Fisher D, Piette J and Dulić V: Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J. 22:3992–4002. 2003. View Article : Google Scholar : PubMed/NCBI
41.	Robertson KA, Bullock HA, Xu Y, et al: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 61:2220–2225. 2001.PubMed/NCBI
42.	Kamata Y, Yamamoto M, Kawakami F, Tsuboi R, Takeda A, Ishihara K and Hibino T: Bleomycin hydrolase is regulated biphasically in a differentiation- and cytokine-dependent manner: relevance to atopic dermatitis. J Biol Chem. 286:8204–8212. 2011. View Article : Google Scholar : PubMed/NCBI
43.	Kamata Y, Maejima H, Watarai A, Saito N, Katsuoka K, Takeda A and Ishihara K: Expression of bleomycin hydrolase in keratinization disorders. Arch Dermatol Res. 304:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
44.	Suszynska J, Tisonczyk J, Lee HG, Smith MA and Jakubowski H: Reduced homocysteine-thiolactonase activity in Alzheimer’s disease. J Alzheimers Dis. 19:1177–1183. 2010.PubMed/NCBI
45.	Towne CF, York IA, Watkin LB, Lazo JS and Rock KL: Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses. J Immunol. 178:6923–6930. 2007. View Article : Google Scholar : PubMed/NCBI
46.	Kamata Y, Taniguchi A, Yamamoto M, et al: Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem. 284:12829–12836. 2009. View Article : Google Scholar : PubMed/NCBI
47.	Zimny J, Sikora M, Guranowski A and Jakubowski H: Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J Biol Chem. 281:22485–224892. 2006. View Article : Google Scholar : PubMed/NCBI
48.	Ratovitski T, Chighladze E, Waldron E, Hirschhorn RR and Ross CA: Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem. 286:12578–12589. 2011. View Article : Google Scholar : PubMed/NCBI